Related News
Home » Business » Manufacturing
Glaxo's breast cancer drug gets second chance
Source: Agencies |
July 10, 2009, Friday
|
Print Edition
Print Edition
BRITAIN'S cost-effectiveness watchdog is to reconsider a decision blocking the use of GlaxoSmithKline's breast cancer drug Tyverb on the National Health Service.
The National Institute for Health Clinical Excellence (NICE), which assesses drugs for reimbursement on the state health service, had ruled in March that the treatment had limited benefits and was too expensive.
But parts of a Glaxo appeal against the decision have been upheld in the light of new supplementary NICE advice for the assessment of treatments in small patient populations with a short life expectancy, the agency said yesterday.
The move means Glaxo will have a fresh opportunity to make a full submission to NICE under the new end of life criteria.
The National Institute for Health Clinical Excellence (NICE), which assesses drugs for reimbursement on the state health service, had ruled in March that the treatment had limited benefits and was too expensive.
But parts of a Glaxo appeal against the decision have been upheld in the light of new supplementary NICE advice for the assessment of treatments in small patient populations with a short life expectancy, the agency said yesterday.
The move means Glaxo will have a fresh opportunity to make a full submission to NICE under the new end of life criteria.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
